1. Home
  2. VRCA vs BSEM Comparison

VRCA vs BSEM Comparison

Compare VRCA & BSEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

HOLD

Current Price

$3.79

Market Cap

88.0M

Sector

Health Care

ML Signal

HOLD

Logo BioStem Technologies Inc. Common Stock

BSEM

BioStem Technologies Inc. Common Stock

N/A

Current Price

$2.04

Market Cap

76.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VRCA
BSEM
Founded
2013
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
88.0M
76.9M
IPO Year
2018
2026

Fundamental Metrics

Financial Performance
Metric
VRCA
BSEM
Price
$3.79
$2.04
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
★ $13.83
N/A
AVG Volume (30 Days)
45.3K
★ 159.4K
Earning Date
11-13-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $35,577,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$58.01
$87.68
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 370.22
N/A
52 Week Low
$3.28
$1.88
52 Week High
$9.82
$5.44

Technical Indicators

Market Signals
Indicator
VRCA
BSEM
Relative Strength Index (RSI) 35.23 27.85
Support Level N/A N/A
Resistance Level $5.94 $4.12
Average True Range (ATR) 0.35 0.35
MACD -0.05 -0.11
Stochastic Oscillator 19.48 5.93

Price Performance

Historical Comparison
VRCA
BSEM

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

About BSEM BioStem Technologies Inc. Common Stock

BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.

Share on Social Networks: